Saul Shiffman1. 1. Pinney Associates, 201 North Craig Street, Suite 320, Pittsburgh, PA 15213, USA. shiffman@pinneyassociates.com
Abstract
BACKGROUND:Nicotine replacement therapy (NRT) has been proven to be effective in heterogeneous groups of smokers. However, analyses have not specifically examined efficacy among light smokers (< or =15 cigarettes per day). The objective of this study is to assess the efficacy of a nicotine lozenge in light smokers. METHODS: We conducted a secondary analysis of a randomized, placebo-controlled clinical trial contrasting active 2mg nicotine lozenge with placebo, and contrasting lightsmokers (< or =15 cigarettes per day) with moderate-heavy smokers (>15 cigarettes per day). Participants were 917 smokers who smoked their first cigarette >30 min after waking, and were randomized to active (n = 459) orplacebo (n = 458) lozenge. Biochemically verified continuous abstinence was measured at 6 weeks and 1 year. RESULTS:Nicotine lozenge significantly increased quit rates relative to placebo at 6 weeks (45.7% versus 31.1%; OR = 1.9 [1.3-2.8]) and at 1 year (19.2% versus 10.0%; OR = 2.3 [1.3-4.0]) among light smokers. Efficacy among light smokers did not differ from that among heavier smokers (ps>0.50). CONCLUSION: The nicotine lozenge is effective for light smokers.
RCT Entities:
BACKGROUND:Nicotine replacement therapy (NRT) has been proven to be effective in heterogeneous groups of smokers. However, analyses have not specifically examined efficacy among light smokers (< or =15 cigarettes per day). The objective of this study is to assess the efficacy of a nicotine lozenge in light smokers. METHODS: We conducted a secondary analysis of a randomized, placebo-controlled clinical trial contrasting active 2mg nicotine lozenge with placebo, and contrasting light smokers (< or =15 cigarettes per day) with moderate-heavy smokers (>15 cigarettes per day). Participants were 917 smokers who smoked their first cigarette >30 min after waking, and were randomized to active (n = 459) or placebo (n = 458) lozenge. Biochemically verified continuous abstinence was measured at 6 weeks and 1 year. RESULTS:Nicotine lozenge significantly increased quit rates relative to placebo at 6 weeks (45.7% versus 31.1%; OR = 1.9 [1.3-2.8]) and at 1 year (19.2% versus 10.0%; OR = 2.3 [1.3-4.0]) among light smokers. Efficacy among light smokers did not differ from that among heavier smokers (ps>0.50). CONCLUSION: The nicotine lozenge is effective for light smokers.
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia Journal: J Natl Cancer Inst Date: 2012-01-25 Impact factor: 13.506
Authors: Emily L Zale; Michelle L Dorfman; W Michael Hooten; David O Warner; Michael J Zvolensky; Joseph W Ditre Journal: Nicotine Tob Res Date: 2014-10-25 Impact factor: 4.244
Authors: Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2012-11-29 Impact factor: 3.913
Authors: Laurie Krupski; K Michael Cummings; Andrew Hyland; Shannon Carlin-Menter; Benjamin A Toll; Martin C Mahoney Journal: Nicotine Tob Res Date: 2013-03-11 Impact factor: 4.244
Authors: Jon O Ebbert; Herbert H Severson; Ivana T Croghan; Brian G Danaher; Darrell R Schroeder Journal: Nicotine Tob Res Date: 2009-10-30 Impact factor: 4.244